 | This article includes a list of references, related reading or external links, but its sources remain unclear because it lacks inline citations .(April 2021) (Learn how and when to remove this template message) |
Erik Tambuyzer (born 1949) is a Belgian bio-engineer and businessman. He is Chairman of the Board of the Flemish Center for Medical Innovation (CMI).
Tambuyzer holds a doctoral degree in bio-industrial sciences from the Katholieke Universiteit Leuven, (Leuven, Belgium).
Having started his professional career at Baxter Healthcare (Baxter-Travenol in Europe) in 1977, Tambuyzer pursued his career six years later at Innovi NV (Brussels, Belgium), a technology management and consultancy company. He also worked as a consultant on biotechnology for minister-president Gaston Geens of the Flemish government. In 1985 he made the business plan and co-founded, together with Hugo Van Heuverswyn, the healthcare biotech company Innogenetics NV (Ghent, Belgium), of which he was General Manager until 1992, at which time he joined Genzyme. He was Senior Vice President Corporate Affairs for Genzyme Europe and International, and a member of the European Management Committee of Genzyme Corporation until 2010, when he joined the Flemish Center for Medical Innovation (CMI).
Tambuyzer is a founding Board member and past Chairman of EuropaBio, the European Association for Bioindustries, and founder of the Ethics Working Group of this Association, as well as the Chair of the joint EBE/EFPIA-EuropaBio Orphan medicines Task Force. He is also Vice-Chair of EPPOSI, the European Platform for Patients' Organizations, Science & Industry. He published on policies regarding orphan medicines and advanced therapies in Europe and internationally, on the European Clinical Trial Directive, and on the impact of biotechnology on healthcare systems.
EuropaBio is Europe's largest and most influential biotech industry group, whose members include Monsanto, Bayer and other biotechnology companies. The organisation was initiated in 1996 to represent the interests of the biotechnology industry at European level and therefore influence legislation that serves the interests of biotechnology companies in Europe.
Sanofi Genzyme is an American biotechnology company based in Cambridge, Massachusetts. Since its acquisition in 2011, Genzyme has been a fully owned subsidiary of Sanofi. In 2010, Genzyme was the world’s third-largest biotechnology company, employing more than 11,000 people around the world. As a subsidiary of Sanofi, Genzyme has a presence in approximately 65 countries, including 17 manufacturing facilities and 9 genetic-testing laboratories. Its products are also sold in 90 countries. In 2007, Genzyme generated $3.8 billion in revenue with more than 25 products on the market. In 2006 and 2007, Genzyme was named one of Fortune Magazine’s “100 Best Companies to Work for”. The company donated $83 million worth of products worldwide; in 2006, it made $11 million in cash donations. In 2005, Genzyme was awarded the National Medal of Technology, the highest level of honor awarded by the president of the United States to America’s leading innovators.
Sheridan Gray Snyder OBE is an entrepreneur, venture capitalist, and philanthropist. in the biotechnology industry. He is the founder and CEO of Biocatalyst, but also a "serial entrepreneur", a founder of Genzyme and many other companies. Snyder, who was the University of Virginia's best tennis player when he was studying for his BA in French and Romance Languages there in the 1960s, made "major contributions to the popularisation of tennis in the USA." He co-founded the National Junior Tennis League that reaches 250,000 inner-city young people and constructed a new tennis center at the University of Virginia.
VIB is a research institute located in Flanders, Belgium. It was founded by the Flemish government in 1995, and became a full-fledged institute on 1 January 1996. The main objective of VIB is to strengthen the excellence of Flemish life sciences research and to turn the results into new economic growth. VIB spends almost 80% of its budget on research activities, while almost 12% is spent on technology transfer activities and stimulating the creation of new businesses, in addition VIB spends approximately 2% on socio-economic activities.
flanders.bio, founded in 2004, is the networking organisation for the life sciences sector in Flanders and represents and supports around 350 member companies. The key strategic objectives of flanders.bio are knowledge exchange and valorisation, human capital development, internationalization of the cluster activities and visibility, familiarization of the public with products derived from the sector and the further development of a supportive environment for the members of flanders.bio.
Dr. Rudi Pauwels is a Belgian pharmacologist and serial biotech entrepreneur. Throughout his successful career of over 35 years in both academia and the biotech/pharmaceutical industry, he has been driven by his passion to advance healthcare with innovative and integrative approaches for current and future medical needs. Together with multi-disciplinary teams of scientific, technological and clinical experts, he generates solutions for the healthcare market that are benefitting many patients around the world. His track-record demonstrates that his approach also created significant value for all stake- and shareholders.
Science and technology in Flanders, being the Flemish Community and more specifically the northern region of Belgium (Europe), is well developed with the presence of several universities and research institutes. These are strongly spread over all Flemish cities, from Kortrijk and Bruges in the Western side, over Ghent as a major university center alongside Antwerp, Brussels and Leuven to Hasselt and Diepenbeek in the Eastern side.
Staf Van Reet is a Belgian scientist and businessman. Currently he is Managing Director of the biotech company Viziphar Biosciences BVBA, and member of the Board of Directors of Janssen Pharmaceutica and the VIB. He was succeeded as Chairman of FlandersBio by Johan Cardoen.
Rudi Mariën is a Belgian scientist and businessman. He is Chairman of the Belgian biotech company Innogenetics.
BIO.be, the Belgian Association for Bioindustries is a Belgian non-profit organization of companies and professionals involved in biotechnology, and those servicing the biotechnology community. The organization works on innovation and entrepreneurship in the biotech industry. The headquarters of the organization are located in Brussels. The chairman is Philippe Stas (AlgoNomics) and the Secretary General is Hugo Francq.
Reinhilde Veugelers is a Belgian economist and Professor of Managerial Economics, Strategy and Innovation at the Katholieke Universiteit Leuven from Belgium, known for her research on science and innovation.
Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, businessman, and investor.
BioMotiv is an accelerator company associated with The Harrington Project, a $340 million initiative centered at University Hospitals of Cleveland. Therapeutic opportunities are identified through relationships with The Harrington Discovery Institute, university and research institutions, disease foundations, and industry sources. Once opportunities are identified, BioMotiv oversees the development, funding, active management, and partnering of the therapeutic products.
Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, alumni. Termeer is "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.
Gerardo Jiménez Sánchez is a Mexican-born pediatrician, scientist and businessman. Along with David Valle and Barton Childs, he completed the first medical analysis of the human genome. He was founder and director of the first National Institute of Genomic Medicine in Latin America (INMEGEN) and leader of the team that developed the Genomic Map of the Mexican Population.
The Biotechnology Innovation Organization (BIO) is the largest trade organization in the world that represents the biotechnology industry. It was founded in 1993 as the Biotechnology Industry Organization, and changed its name to the Biotechnology Innovation Organization on January 4, 2016. Biotechnology Innovation Organization serves more than 1,100 biotechnology firms, research schools, state biotechnology centers and related associations in the United States and in more than 30 other countries.
Shenzhen International BT Leadership Summit is a biology-focused business conference. It is held each year in September. It is arranged by the Shenzhen Municipal People's Government. It is held at the Shenzhen Convention and Exhibition Center.
Jeffrey Leiden, M.D., Ph.D. is the executive chairman of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts. He was initially appointed to the board of directors of the company in 2009 and was CEO and president from February 2012 to March 2020.
Frederick Frank CFA is an investment banker, with more than 50 years of experience on Wall Street. He is considered the first investment banker to have specialized in the areas of biotechnology, pharmaceuticals, and health care services.
Moncef Mohamed Slaoui is a Moroccan-born Belgian-American researcher who served as the Head of Operation Warp Speed under President Donald Trump from 2020 to 2021.